Patents Assigned to Infinity Pharmaceuticals, Inc.
  • Methods of use of cyclopamine analogs
    Patent number: 8017648
    Abstract: The invention provides methods for treating various conditions using derivatives of cyclopamine having the following formula:
    Type: Grant
    Filed: December 27, 2007
    Date of Patent: September 13, 2011
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Michael J. Grogan, Karen J. McGovern, Martin Tremblay
  • Analogs of benzoquinone-containing ansamycins and methods of use thereof
    Patent number: 8003634
    Abstract: The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase the solubility and air stability of the resulting 17-ammonium hydroquinone ansamycin analog.
    Type: Grant
    Filed: October 6, 2010
    Date of Patent: August 23, 2011
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Julian Adams, Yun Gao, Asimina T. Georges Evangelinos, Louis Grenier, Roger H. Pak, James R. Porter, James L. Wright
  • TREATMENT OF FIBROTIC CONDITIONS USING HEDGEHOG INHIBITORS
    Publication number: 20110183948
    Abstract: Provided is a method of treating a fibrotic condition with a hedgehog inhibitor.
    Type: Application
    Filed: January 14, 2011
    Publication date: July 28, 2011
    Applicant: INFINITY PHARMACEUTICALS, INC.
    Inventors: Arnold J. Levine, Elizabeth Guilfoyle Trehu
  • Ansamycin formulations and methods of use thereof
    Patent number: 7947670
    Abstract: Provided herein, inter alia, are solid forms of geldanamycin analogs, pharmaceutical compositions comprising a geldanamycin analog and a crystallization inhibitor, methods of making and using such compositions. Additionally, provided are methods for the treatment of cancer, a neoplastic disease state and/or a hyperproliferative disorder, and methods of inhibiting Heat Shock Protein 90 (“Hsp90”).
    Type: Grant
    Filed: December 11, 2007
    Date of Patent: May 24, 2011
    Assignee: Infinity Pharmaceuticals Inc.
    Inventors: Brian C. Austad, Louis Grenier, Edward B. Holson, John J. Lee, Roger H. Pak, James R. Porter, James L. Wright
  • Inhibitors of fatty acid amide hydrolase
    Patent number: 7947663
    Abstract: The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof.
    Type: Grant
    Filed: October 10, 2007
    Date of Patent: May 24, 2011
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Julian Adams, Mark L. Behnke, Alfredo C. Castro, Catherine A. Evans, Louis Grenier, Michael J. Grogan, Tao Liu, Daniel A. Snyder, Thomas T. Tibbitts
  • COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF CANCER
    Publication number: 20110118298
    Abstract: Described herein are compositions, kits, and methods for determining whether subjects having cancer(s) are likely to respond to treatment with an HSP90 inhibitor, as a single agent or in combination therapy. Further described are methods for prognosing a time course of disease in a subject having such cancer.
    Type: Application
    Filed: November 12, 2010
    Publication date: May 19, 2011
    Applicant: INFINITY PHARMACEUTICALS, INC.
    Inventors: Christian Fritz, Emmanuel Y. Normant, Juan Guillermo Paez, Kip A. West
  • ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE
    Publication number: 20110034437
    Abstract: The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient. The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
    Type: Application
    Filed: May 18, 2010
    Publication date: February 10, 2011
    Applicant: Infinity Pharmaceuticals, Inc.
    Inventors: Mark L. Behnke, Alfredo C. Castro, Lawrence K. Chan, Catherine A. Evans, Louis Grenier, Michael J. Grogan, Yves Leblanc, Tao Liu, Stephane Peluso, Daniel A. Snyder, Thomas T. Tibbitts
  • ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE
    Publication number: 20110028482
    Abstract: The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient. The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
    Type: Application
    Filed: May 18, 2010
    Publication date: February 3, 2011
    Applicant: Infinity Pharmaceuticals, Inc.
    Inventors: Mark L. Behnke, Alfredo C. Castro, Lawrence K. Chan, Catherine A. Evans, Louis Grenier, Michael J. Grogan, Yves Leblanc, Tao Liu, Stephane Peluso, Daniel A. Snyder, Thomas T. Tibbitts
  • ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE
    Publication number: 20110028478
    Abstract: The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient. The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
    Type: Application
    Filed: May 18, 2010
    Publication date: February 3, 2011
    Applicant: Infinity Pharmaceuticals, Inc.
    Inventors: Mark L. Behnke, Alfredo C. Castro, Lawrence K. Chan, Catherine A. Evans, Louis Grenier, Michael J. Grogan, Yves Leblanc, Tao Liu, Stephane Peluso, Daniel A. Snyder, Thomas T. Tibbitts
  • Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
    Patent number: 7851637
    Abstract: One aspect of the present invention relates to heterocyclic compounds that bind to bcl proteins and inhibit Bcl function. Another aspect of the present invention relates to compositions comprising a heterocyclic compound of the invention. The present invention provides methods for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Grant
    Filed: June 17, 2005
    Date of Patent: December 14, 2010
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Wei Deng, Kristopher M. Depew, Michael A. Foley, Christian C. Fritz, Asimina T. Georges Evangelinos, Michael J. Grogan, Nafeeza Hafeez, Edward B. Holson, Brian T. Hopkins, Nii O. Koney, Tao Liu, David A. Mann, Lisa A. Marcaurelle, Daniel A. Snyder, Dennis J. Underwood, Andrew A. Wylie, Lin-Chen Yu, Linping Zhang
  • Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
    Patent number: 7842815
    Abstract: One aspect of the present invention relates to heterocyclic compounds that bind to bcl proteins and inhibit Bcl function. Another aspect of the present invention relates to compositions comprising a heterocyclic compound of the invention. The present invention provides methods for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Grant
    Filed: November 15, 2006
    Date of Patent: November 30, 2010
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Edward B. Holson, Brian T. Hopkins, Nii O. Koney, Daniel A. Snyder, Thomas T. Tibbitts
  • Analogs of benzoquinone-containing ansamycins and methods of use thereof
    Patent number: 7833997
    Abstract: The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase the solubility and air stability of the resulting 17-ammonium hydroquinone ansamycin analog.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: November 16, 2010
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Julian Adams, Yun Gao, Asimina T. Georges Evangelinos, Louis Grenier, Roger H. Pak, James R. Porter, James L. Wright
  • METHODS OF USE OF CYCLOPAMINE ANALOGS
    Publication number: 20100286180
    Abstract: The invention provides methods for treating various conditions using derivatives of cyclopamine having the following formula:
    Type: Application
    Filed: December 27, 2007
    Publication date: November 11, 2010
    Applicants: Infinity Pharmaceuticals, Inc., Johns Hopkins University
    Inventors: Alfredo C. Castro, Michael J. Grogan, William Matsui, Karen J. McGovern, Martin Tremblay
  • Cyclopamine analogs
    Patent number: 7812164
    Abstract: The invention provides novel derivatives of cyclopamine having the following formula:
    Type: Grant
    Filed: December 27, 2007
    Date of Patent: October 12, 2010
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Brian Austad, Mark L. Behnke, Alfredo C. Castro, Michael J. Grogan, Somarajannair Janardanannair, Andre Lescarbeau, Stephane Peluso, Martin Tremblay
  • Analogs of benzoquinone-containing ansamycins and methods of use thereof
    Patent number: 7767662
    Abstract: The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase the solubility and air stability of the resulting 17-ammonium hydroquinone ansamycin analog.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: August 3, 2010
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Julian Adams, Yun Gao, Asimina T. Georges Evangelinos, Louis Grenier, Roger H. Pak, James R. Porter, James L. Wright
  • Analogs of benzoquinone-containing ansamycins and methods of use thereof
    Patent number: 7767663
    Abstract: The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase the solubility and air stability of the resulting 17-ammonium hydroquinone ansamycin analog.
    Type: Grant
    Filed: February 11, 2009
    Date of Patent: August 3, 2010
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Julian Adams, Yun Gao, Asimina T. Georges Evangelinos, Louis Grenier, Roger H. Pak, James R. Porter, James L. Wright
  • Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners
    Publication number: 20100190791
    Abstract: The present invention relates to heterocyclic compounds that bind to Bcl proteins and inhibit Bcl function, compositions comprising such compounds, and methods for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Application
    Filed: April 2, 2010
    Publication date: July 29, 2010
    Applicant: INFINITY PHARMACEUTICALS, INC.
    Inventors: ALFREDO C. CASTRO, MICHAEL J. GROGAN, EDWARD B. HOLSON, BRIAN T. HOPKINS, NII O. KONEY, STEPHANE PELUSO, DANIEL A. SNYDER
  • Analogs of benzoquinone-containing ansamycins and methods of use thereof
    Patent number: 7691840
    Abstract: The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase the solubility and air stability of the resulting 17-ammonium hydroquinone ansamycin analog.
    Type: Grant
    Filed: February 11, 2009
    Date of Patent: April 6, 2010
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Julian Adams, Yun Gao, Asimina T. Georges Evangelinos, Louis Grenier, Roger H. Pak, James R. Porter, James L. Wright
  • Analogs of benzoquinone-containing ansamycins and methods of use thereof
    Patent number: 7608613
    Abstract: The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase the solubility and air stability of the resulting 17-ammonium hydroquinone ansamycin analog.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: October 27, 2009
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Julian Adams, Yun Gao, Asimina T. Georges Evangelinos, Louis Grenier, Roger H. Pak, James R. Porter, James L. Wright
  • Analogs of benzoquinone-containing ansamycins and methods of use thereof
    Patent number: 7579337
    Abstract: The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase the solubility and air stability of the resulting 17-ammonium hydroquinone ansamycin analog.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: August 25, 2009
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Julian Adams, Yun Gao, Asimina T. Georges Evangelinos, Louis Grenier, Roger H. Pak, James R. Porter, James L. Wright